Tag:

NICE

Latest Headlines

Latest Headlines

Can clot-fighters get a boost from the U.K.'s new enthusiasm?

The cost-effectiveness watchdogs in the U.K. really, really want people to take their clot-busting drugs. Days ago, the National Institute for Health and Care Excellence touted the benefits of anticoagulants for patients with atrial fibrillation, and now, they're considering new backing for Eli Lilly's Effient.

NICE backs thousands more scripts for clot-fighters Pradaxa, Xarelto, and Eliquis

While their makers fight lawsuits and regulators keep watch on safety questions, the U.K.'s cost-effectiveness gatekeepers figure the new generation of anticoagulants should be used more to fight stroke, not less.

U.K. gatekeepers nix hep C drug Sovaldi till Gilead ponies up more evidence

Should the British health service pay for the expensive-yet-effective hepatitis C treatment Sovaldi? The U.K.'s cost-effectiveness gatekeepers say they're not convinced.

U.K. price watchdog changes its tune on BMS melanoma blockbuster Yervoy

Three months after Britain's National Institute for Health and Care Excellence said it would not recommend Bristol-Myers Squibb's Yervoy as a first-line treatment for melanoma, the much-feared cost-effectiveness agency has changed its mind. A new draft guidance from NICE now says Yervoy should be available as the first choice for treating patients with advanced melanoma.

MS docs, activists pressure U.K. cost watchdog to bless Biogen, GW meds

The U.K.'s cost-effectiveness agency is accustomed to boos and hisses. The National Institute for Health and Care Excellence often turns down new treatments it considers too expensive for their payoff in patients. So, will a campaign by patient advocates sway its opinion on two new multiple sclerosis drugs?

Sanofi's new MS med scores a spot on U.K.'s NHS formulary

Sanofi felt the sting of lost sales potential when the FDA nixed its multiple sclerosis treatment Lemtrada in December. But the EU sees things a bit differently, and now a new nod from Britain's cost watchdog has unlocked some new top-line potential.

eNeura receives 510(k) for second-generation migraine treatment device

Following the FDA's de novo approval of eNeura's device for the treatment of pain from migraine headaches with aura, the company announced May 23 that its second-generation SpringTMS received 510(k) clearance. 

U.K.'s NICE throws Astellas a bone on Xtandi--or does it?

First it was good news, then it was bad news, and now it's good news again for Astellas' prostate cancer treatment Xtandi (enzalutamide) and its recommendation from the U.K.'s National Institute for Health and Care Excellence. At least it appears that way.

NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations

Let the price negotiations begin, the top executive for the U.K. price watchdog suggested today after the agency nixed Roche's pioneering breast cancer drug Kadcyla as too expensive.

British cost watchdog backtracks again on Roche's Tarceva

After intitially recommending Roche's targeted cancer drug Tarceva for use by Britain's National Health Service, the U.K.'s National Institute for Health and Care Excellence said in February it was reviewing the recommendation. Now, it looks likely to revert back to its original stance--a reversal of fortune the Swiss drugmaker is pleased with.